UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 69.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,114 shares of the company’s stock after selling 46,948 shares during the quarter. JPMorgan Chase & Co. owned about 0.09% of UroGen Pharma worth $225,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Rosalind Advisors Inc. acquired a new stake in UroGen Pharma during the 4th quarter worth approximately $9,266,000. Geode Capital Management LLC raised its stake in shares of UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after acquiring an additional 34,248 shares in the last quarter. ARK Investment Management LLC boosted its holdings in UroGen Pharma by 15.2% in the fourth quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock valued at $1,493,000 after purchasing an additional 18,514 shares during the period. Bank of New York Mellon Corp grew its stake in UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after purchasing an additional 3,024 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Trading Up 0.9 %

NASDAQ URGN opened at $11.51 on Friday. UroGen Pharma Ltd. has a 12 month low of $8.94 and a 12 month high of $20.70. The company has a market capitalization of $530.69 million, a price-to-earnings ratio of -3.65 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm’s fifty day moving average price is $10.54 and its 200 day moving average price is $11.06.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, sell-side analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

URGN has been the subject of several recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, April 28th. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of UroGen Pharma in a research report on Monday, April 28th. Scotiabank initiated coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price objective for the company. Finally, The Goldman Sachs Group dropped their target price on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $32.86.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.